Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B-cell lymphoma

Rákkutatás · Diffuse large B-cell lymphoma

CCR5 expression in about one‑third of patients with primary intestinal diffuse large B‑cell lymphoma was associated with worse event‑free survival and overall survival, and correlated with an M2‑dominant tumor microenvironment.

The study investigated potential molecular markers and immune cell composition within the tumor microenvironment (TME) of primary intestinal diffuse large B‑cell lymphoma (PI‑DLBCL). CCR5 expression, found in about one‑third of patients, was associated with lower complete response rates to first‑line immunochemotherapy and worse event‑free survival (EFS) and overall survival (OS). CCR5-positive tumors exhibited decreased CD86‑positive (M1‑like) and increased CD206‑positive (M2‑like) macrophage infiltration, indicating an immunosuppressive TME. Multivariate analyses confirmed CCR5 expression as an independent adverse prognostic factor, identifying a biologically aggressive PI‑DLBCL subtype.

CCR5 expression serves as a prognostic biomarker and potential therapeutic target in primary intestinal DLBCL, guiding risk stratification and personalized treatment strategies.

Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.

Eredeti forrás

Kapcsolódó jelek